Targeting the BAFF/APRIL cytokine network in multiple myeloma

Stephen A. Mihalcik, Diane F Jelinek

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The BAFF/APRIL cytokine network is intimately linked through three different receptors to the survival and fi tness of B lineage cells, from the first expression of a complete B cell receptor to their differentiation to memory B and plasma cells. The speci fi c, pervasive, and survival-linked nature of the relationship between B lineage cells and this cytokine network make it both a likely disease modi fi er and a tantalizing target for therapeutic intervention in humoral immune pathologies. Some current therapeutics directly targeting the BAFF/APRIL cytokine network have been developed and undergone clinical trials in the context of autoimmunity with some limited success. Despite a powerful rationale and a constantly deepening mechanistic understanding of the BAFF/APRIL cytokine network in normal and malignant plasma cells, trials of cytokine network-targeted therapeutics in multiple myeloma are still in their infancy and have shown only minor promise. There is signi fi cantly greater potential in inhibiting NF-kB, a downstream mediator of BAFF/APRIL signals.

Original languageEnglish (US)
Title of host publicationAdvances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science
PublisherSpringer New York
Pages187-202
Number of pages16
ISBN (Print)9781461446668, 9781461446651
DOIs
StatePublished - Jan 1 2013

Fingerprint

Multiple Myeloma
Cytokines
Plasma Cells
B-Lymphocytes
NF-kappa B
Autoimmunity
Therapeutics
Clinical Trials
Pathology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mihalcik, S. A., & Jelinek, D. F. (2013). Targeting the BAFF/APRIL cytokine network in multiple myeloma. In Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science (pp. 187-202). Springer New York. https://doi.org/10.1007/978-1-4614-4666-8_10

Targeting the BAFF/APRIL cytokine network in multiple myeloma. / Mihalcik, Stephen A.; Jelinek, Diane F.

Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York, 2013. p. 187-202.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mihalcik, SA & Jelinek, DF 2013, Targeting the BAFF/APRIL cytokine network in multiple myeloma. in Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York, pp. 187-202. https://doi.org/10.1007/978-1-4614-4666-8_10
Mihalcik SA, Jelinek DF. Targeting the BAFF/APRIL cytokine network in multiple myeloma. In Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York. 2013. p. 187-202 https://doi.org/10.1007/978-1-4614-4666-8_10
Mihalcik, Stephen A. ; Jelinek, Diane F. / Targeting the BAFF/APRIL cytokine network in multiple myeloma. Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York, 2013. pp. 187-202
@inbook{fd9457212c9045b2b96a3ba8fc78db7e,
title = "Targeting the BAFF/APRIL cytokine network in multiple myeloma",
abstract = "The BAFF/APRIL cytokine network is intimately linked through three different receptors to the survival and fi tness of B lineage cells, from the first expression of a complete B cell receptor to their differentiation to memory B and plasma cells. The speci fi c, pervasive, and survival-linked nature of the relationship between B lineage cells and this cytokine network make it both a likely disease modi fi er and a tantalizing target for therapeutic intervention in humoral immune pathologies. Some current therapeutics directly targeting the BAFF/APRIL cytokine network have been developed and undergone clinical trials in the context of autoimmunity with some limited success. Despite a powerful rationale and a constantly deepening mechanistic understanding of the BAFF/APRIL cytokine network in normal and malignant plasma cells, trials of cytokine network-targeted therapeutics in multiple myeloma are still in their infancy and have shown only minor promise. There is signi fi cantly greater potential in inhibiting NF-kB, a downstream mediator of BAFF/APRIL signals.",
author = "Mihalcik, {Stephen A.} and Jelinek, {Diane F}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-4666-8_10",
language = "English (US)",
isbn = "9781461446668",
pages = "187--202",
booktitle = "Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science",
publisher = "Springer New York",

}

TY - CHAP

T1 - Targeting the BAFF/APRIL cytokine network in multiple myeloma

AU - Mihalcik, Stephen A.

AU - Jelinek, Diane F

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The BAFF/APRIL cytokine network is intimately linked through three different receptors to the survival and fi tness of B lineage cells, from the first expression of a complete B cell receptor to their differentiation to memory B and plasma cells. The speci fi c, pervasive, and survival-linked nature of the relationship between B lineage cells and this cytokine network make it both a likely disease modi fi er and a tantalizing target for therapeutic intervention in humoral immune pathologies. Some current therapeutics directly targeting the BAFF/APRIL cytokine network have been developed and undergone clinical trials in the context of autoimmunity with some limited success. Despite a powerful rationale and a constantly deepening mechanistic understanding of the BAFF/APRIL cytokine network in normal and malignant plasma cells, trials of cytokine network-targeted therapeutics in multiple myeloma are still in their infancy and have shown only minor promise. There is signi fi cantly greater potential in inhibiting NF-kB, a downstream mediator of BAFF/APRIL signals.

AB - The BAFF/APRIL cytokine network is intimately linked through three different receptors to the survival and fi tness of B lineage cells, from the first expression of a complete B cell receptor to their differentiation to memory B and plasma cells. The speci fi c, pervasive, and survival-linked nature of the relationship between B lineage cells and this cytokine network make it both a likely disease modi fi er and a tantalizing target for therapeutic intervention in humoral immune pathologies. Some current therapeutics directly targeting the BAFF/APRIL cytokine network have been developed and undergone clinical trials in the context of autoimmunity with some limited success. Despite a powerful rationale and a constantly deepening mechanistic understanding of the BAFF/APRIL cytokine network in normal and malignant plasma cells, trials of cytokine network-targeted therapeutics in multiple myeloma are still in their infancy and have shown only minor promise. There is signi fi cantly greater potential in inhibiting NF-kB, a downstream mediator of BAFF/APRIL signals.

UR - http://www.scopus.com/inward/record.url?scp=84948145284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948145284&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4666-8_10

DO - 10.1007/978-1-4614-4666-8_10

M3 - Chapter

AN - SCOPUS:84948145284

SN - 9781461446668

SN - 9781461446651

SP - 187

EP - 202

BT - Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science

PB - Springer New York

ER -